Warning: The NCBI web site requires JavaScript to function. more...
What do biomarkers tell us about the pathogenesis of ankylosing spondylitis?
Maksymowych WP.
Arthritis Res Ther. 2009;11(1):101. Epub 2009 Jan 7.
Related citations
Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.
Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J.
Arthritis Res Ther. 2008;10(5):R125. Epub 2008 Oct 22.
Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH, Lee HJ, Sung IH, Kim TH.
J Rheumatol. 2007 Aug;34(8):1753-9. Epub 2007 Jun 15.
Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
Kim TH, Stone M, Payne U, Zhang X, Ionescu M, Lobanok T, King L, Poole AR, Inman RD.
Arthritis Rheum. 2005 Mar;52(3):885-91.
Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?
Wendling D, Toussirot E.
J Rheumatol. 2007 Aug;34(8):1647-9. No abstract available.
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J.
Ann Rheum Dis. 2008 Apr;67(4):511-7. Epub 2007 Jul 20.
Can we stop progression of ankylosing spondylitis?
Schett G, Rudwaleit M.
Best Pract Res Clin Rheumatol. 2010 Jun;24(3):363-71.
Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation.
Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG.
Arthritis Rheum. 2009 Jan;60(1):93-102.
Can structural damage be prevented in ankylosing spondylitis?
Sieper J.
Curr Opin Rheumatol. 2009 Jul;21(4):335-9. Review.
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.
Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J.
Arthritis Rheum. 2006 Feb;54(2):678-81. No abstract available.
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.
Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J.
Arthritis Res Ther. 2008;10(5):R104. Epub 2008 Sep 1.
Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, Wong RL, Inman RD; M03-606 Study Group.
J Rheumatol. 2008 Oct;35(10):2030-7. Epub 2008 Sep 1.
Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab.
Appel H, Hermann KG, Althoff CE, Rudwaleit M, Sieper J.
J Rheumatol. 2007 Dec;34(12):2497-8. No abstract available.
Disease modification in ankylosing spondylitis.
Nat Rev Rheumatol. 2010 Feb;6(2):75-81. Review.
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
Sieper J, Appel H, Braun J, Rudwaleit M.
Arthritis Rheum. 2008 Mar;58(3):649-56. Review. No abstract available.
Ankylosing spondylitis.
Braun J, Sieper J.
Lancet. 2007 Apr 21;369(9570):1379-90. Review.
Matrix metalloproteinase expression in the spondyloarthropathies.
Zhu J, Yu DT.
Curr Opin Rheumatol. 2006 Jul;18(4):364-8. Review.
Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics.
Appel H, Sieper J.
Curr Rheumatol Rep. 2008 Oct;10(5):356-63. Review.
[Immunopathology of ankylosing spondylitis and other spondyloarthritides].
Appel H, Loddenkemper C, Sieper J.
Z Rheumatol. 2008 Feb;67(1):25-31. Review. German.
FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment.
Wendling D, Blagosklonov O, Streit G, Lehuédé G, Toussirot E, Cardot JC.
Ann Rheum Dis. 2005 Nov;64(11):1663-5. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on